Pharmaceuticals
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
3673
Sanyou Biopharmaceuticals forged strategic partnership with Dragon Sail Pharmaceutical to upgrade integrated innovative antibody drug R&D
SHANGHAI, June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, aCDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture servic...
2022-06-25 08:00
4996
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
2022-06-24 21:00
3589
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies i...
2022-06-23 20:00
1586
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...
2022-06-19 10:30
3094
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...
2022-06-17 20:00
3843
111, Inc. Announces First Quarter 2022 Unaudited Financial Results
SHANGHAI, June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quart...
2022-06-16 15:58
4187
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...
2022-06-15 22:37
2609
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria
SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it
will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at
the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna,
Austria from 6th to 9th August.
2022-06-14 22:00
1090
Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress
SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting). The recently completed phase 1b stu...
2022-06-14 20:00
1186
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
2022-06-14 19:00
2068
Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province
SUZHOU, China, June 14, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its "clinical trial cooperative research and development and ov...
2022-06-14 12:35
2013
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...
2022-06-13 19:11
2125
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
* In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-...
2022-06-13 19:00
2262
Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform
- 82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after anbal-cel treatment to the patients in relapsed/refractory large B-cell lymphoma - 2 out of 3 patients dosed with 2x105 cells/kg of anbal-cel lasting the complete response for more than 12 months - Well tolerat...
2022-06-13 19:00
1875
Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus
SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inShanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the treatment o...
2022-06-13 09:00
1776
Guojun Lang, CEO of Sanyou: New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
SHANGHAI, June 10, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals officially launched its independently developed Super-Trillion Antibody Libraries (STAL), and the concomitant innovative antibody drug discovery platform. Established by Sanyou after seven years of continuous innovation a...
2022-06-11 08:00
6100
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use ...
2022-06-10 19:00
2830
RAD adds brain tumor technology to portfolio
* Sublicensing of promising imaging & therapeutic radiopharmaceutical from leading US university,Case Western Reserve University (CWRU), Ohio * PTPµ (PTPmu), the target, is a unique biomarker present only in tumor cells but not healthy cells * The radionuclide carrying PTPµ-targeting agent h...
2022-06-10 10:21
2109
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention
BOSTON, June 9, 2022 /PRNewswire/ -- BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation onJune 16, 12:00 at BIO International convention, taking place inSan Diego, California, between June 13-16, 2022. BIORCEHSTRA's company presentation will cover its lead therapeut...
2022-06-09 20:30
2094
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
